Abstract: The present invention relates to a continuous process and a system for macromolecular assembly and capture (refolding or proteins (e.g. refolding of HAT human ?2-microglobulin), hybridization of nucleic acid, nucleic acid analogues, and protein-nucleic acid chimera, aggregation of carbohydrates, and assembly of nanostructures/nanomaterials.

Abstract: A method of refolding proteins from a suspension comprising the proteins in a predominately misfolded form. The method involves adding of a denaturant to the suspension comprising the misfolded proteins to obtain the proteins in a substantially unfolded form. The suspension comprising the unfolded proteins is diluted so as to obtain a mixture where at least part of the proteins are refolded. Subsequently, the refolded proteins can be separated.

Abstract: Method of refolding proteins from a suspension comprising the proteins in a predominantly misfolded form. The method involves adding of a denaturant to the suspension comprising the misfolded proteins to obtain the proteins in a substantially unfolded form. The suspension comprising the unfolded proteins is diluted so as to obtain a mixture where at least part of the proteins are refolded. Subsequently, the refolded proteins can be separated.

Abstract: The present invention relates to the identification of CTL epitopes by the combination of biochemical assays, statistical matrix calculations, and artificial neural networks. A set of peptide libraries are used to generate complete unbiased matrices representing peptide-MHC interactions used to generate a primary prediction of MHC binding for all possible non-redundant peptides. The best binders are subject to a quantitative biochemical binding assay and subsequently a computerised artificial neural network prediction program built from these in vitro experimental MHC-I binding data. The method further comprises improving the identified epitope by replacing amino acids, and testing the identified CTL epitopes in in vitro and in vivo models.

Abstract: The invention relates to a method of producing an antibody or an antibody fragment specifically recognizing a peptide-MHC complex. It also relates to antibodies and antibody fragments according to the invention that are conjugated to a pharmaceutical or to a superantigen. The invention relates to a pharmaceutical composition comprising antibodies or antibody fragments a according to the invention for the prevention or treatment of infectious and autoimmune diseases, cancer and to compositions for the diagnosis of said diseases.

Abstract: A method of identifying potential polypeptide vaccines to an agent, such as viruses, bacteria, and parasites. A critical binding segment of a first polypeptide known to bind to a first MHC type, is ascertained. The effect of replacing each of the amino acids in the critical segment, upon binding of that segment to the first MHC type, is evaluated. Following this, a protein produced by the agent is scanned for at least one trial amino acid sequence which the foregoing evaluation indicates will be a good binder to the first MHC type. When a potentially good binding sequence is found, a polypeptide containing such sequence can be evaluated as a synthetic vaccine.